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Available online 5 April 2016The incidence of Alzheimer's disease (AD) is growing every day and ﬁnding an effective treatment is becoming
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According to the World Alzheimer Report 2015, it was estimated
that 46.8 million people worldwide were living with dementia in 2015
and this number is expected to double every 20 years (Alzheimer's
disease International: World Alzheimer Report). Thus, dementia canal Branch, 301 University Blvd
77555, USA.
. This is an open access article underbe considered a global threat which imposes a tremendous burden on
society and the economy of the world. According to the Alzheimer's
Association, Alzheimer's disease (AD) is the most common cause of
dementia accounting for almost 60 to 80% of dementia cases and is
the sixth leading cause of death in theUnited States. In 2015, the nation-
al cost of ADwas expected to be $220millionwhichby 2050 could reach
up to $1 trillion (Alzheimer's, 2015). The very thin line delineating
normal aging processes and AD have led to the consideration of another
category, mild cognitive impairment (MCI), since both are associated
with memory loss (Mucke, 2009). Neuronal degeneration starts much
earlier than the manifestation of the symptoms and clinical diagnosis.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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revised the criteria and guidelines whichwill better identify the disease
progression from its preclinical stage to the clinical stage (Sperling et al.,
2011). AD is an irreversible, progressive degeneration of brain cells
associated with deterioration of memory that hampers the affected
person's day to day life. The molecular basis of this disease pathology
is highly debated. However, the abnormal accumulation of amyloid-β
(Aβ) into senile plaques and tau proteins into hyperphosphorylated
neuroﬁbrillary tangles has been pathologically identiﬁed and unequivo-
cally accepted as the two major hallmarks of this disease. There are
many risk factors for developing AD pathology with age being the
greatest one. Diabetes, hypertension, and inﬂammation are also risk fac-
tors for AD (Shinohara et al., 2014). Additionally, there are genetic risk
factors for AD including the APOE ɛ4 allele (Bertram et al., 2010). An
ever-growing incidence of AD has led researchers and clinicians to
search for a cure. Studies performed over decades have come to a
consensus that the generation of toxic Aβ is a key event driving AD
pathogenesis. Aβ is a 38 to 43 amino acid long peptide generated by
the sequential proteolytic cleavage of amyloid precursor protein (APP)
byβ- and γ-secretases (Chow et al., 2010). Even though the exact phys-
iological function of APP is not currently identiﬁed, it is well established
that the over-production of Aβ generated from APP plays a role in AD
development. Apart from the over-production, there were two other
pathways shown to regulate Aβ levels in the AD brain: clearance or
degradation of the Aβ produced and its re-entry into the brain.
Therefore, any imbalance in the dynamic equilibrium maintained by
these three pathways would result in the accumulation of Aβ (Yoon
and Jo, 2012; Mucke, 2009). Mutations in genes coding for key proteins
also pose as a risk factor for the development of ADpathology leading to
the formation of amyloids. Almost 25 autosomal dominantmutations in
the APP gene have been found to be pathogenic in familial AD (Jonsson
et al., 2012). Two other important genes, preselinin-1 and preselinin-2,
were found to be associated with cases of familial AD. Mutations in
these two genes alter the proteolytic cleavage of APP, thereby produc-
ing a more aggregation-prone isoform of Aβ (De Strooper et al., 2012).
For a considerable period of time, research in the AD ﬁeld mainly
encompassed the study of senile plaques composed primarily of Aβ
which is one of the characteristic hallmarks of AD and explained by an
earlier version of the amyloid cascade hypothesis. It relied on the fact
that Aβ is released in the extracellular space where it accumulates
into senile plaques leading to the formation of neuroﬁbrillary tangles
of tau protein and causing vascular damage, cell loss, and dementia
(Hardy and Higgins, 1992). But researchers were intrigued by the lack
of correlation between the manifestation of the disease and the plaque
burden. Neuronal death also occurred in brain regions devoid of
plaques. It was then discovered that Aβ plaques were present in
cognitively normal individuals (Erten-Lyons et al., 2009; Sloane et al.,
1997). The existence of non-demented individuals with advanced AD
neuropathology demonstrates that plaque burden does not correspond
to cognition or degeneration. These individuals had signiﬁcant plaque
burden but no memory impairments or changes in brain volume
(Erten-Lyons et al., 2009). Larger insoluble aggregates, such as Aβ
plaques, did not induce memory impairment in the absence of
oligomers in Tg2576mice that develop plaque pathology and behavior-
al deﬁcits at 9–10 months old. In fact, a reduction in oligomer levels
corresponded to improved memory in these mice (Lesné et al., 2008;
Hsiao et al., 1996). Soluble Aβ oligomers, on the other hand, have
been shown to produce cognitive deﬁcits in the absence of plaques
(Gandy et al., 2010). Moreover, there are individuals who appear to
have AD but show no pathological changes in their brains demonstrat-
ing that larger aggregates are not essential to cognitive impairment
(Petersen et al., 2013). These results suggest that larger aggregates are
not responsible for neurodegeneration and that the smaller soluble olig-
omers are the toxic species of Aβ. It was then that the focus of research
shifted to an alternate entity, soluble oligomers of Aβ. Electron micros-
copy and atomic force microscopy revealed that the toxic solubleoligomers are spherical in shape ranging from about 3 to 10 nm. These
spheroidal structures come together forming strings of beads, termed
asprotoﬁbrilswhich also possess toxic effects (Glabe, 2006). In addition,
Aβ1–42 protoﬁbrils but not ﬁbrils were shown to stimulate microglial
production of tumor necrosis factor α suggesting a role for soluble Aβ
aggregates in stimulating inﬂammatory responses and toxicity
(Paranjape et al., 2012). Oligomers of different proteins were reported
to take a common sequence-independent conformationwhich suggests
that a similar mechanism of toxicity would exist for all the amyloid
diseases (Kayed and Glabe, 2006; Chiti and Dobson, 2006; Campioni
et al., 2010). Aβ oligomers exert their toxicity through a variety of
mechanisms including receptor and direct membrane interactions,
reviewed by Kayed and Lasagna-Reeves (2013). At the same time,
many amyloidogenic proteins, such as tau and α-synuclein (α-syn),
also shifted from larger aggregates to oligomers as the toxic species sug-
gesting a universal mechanism of toxicity for amyloid proteins such as
tau (Gerson and Kayed, 2013), α-syn (Sengupta et al., 2015), and TAR
DNA-binding protein 43 (TDP-43) (Choksi et al., 2014; Fang et al.,
2014). We have previously demonstrated that apart from their
individual oligomeric assemblies, different pathogenic proteins also
co-aggregate or form hybrid oligomers including tau with α-syn and
TDP-43 with Aβ, α-syn, and cellular prion protein (PrPc) in AD patients
(Sengupta et al., 2015; Guerrero-Munoz et al., 2014b). For the purpose
of this review we deﬁne oligomers as trimers of Aβ or larger with a
conformation distinct from ﬁbrils. In this review we will discuss
oligomer size and conformation in relation to the current literature on
toxicity, inﬂammation, and immunotherapy with a focus on Aβ but
extending to other amyloid oligomers where the mechanisms seem
universal. We will emphasize the role of spreading oligomers in the
progression of AD.
2. Size, Stability, and Toxicity
A substantial number of investigations aiming to unravel the
mechanism of the disease have accepted an intermediate structure
of aggregated Aβ which is formed earlier than plaques and has
been linked to the pathogenesis (Kayed and Lasagna-Reeves, 2013;
Klein, 2013; Hardy and Selkoe, 2002). Despite various isoforms of
Aβ, with differing propensities for aggregation, three major groups
of Aβ assemblies exist. These three assemblies of Aβ are comprised
of monomers, soluble oligomers, and insoluble ﬁbrils which have
been termed as ‘Aβ pools’. Each pool again encompasses multiple
structures of Aβ aggregation based on various organizations
(reviewed by Goure et al. (2014)). Soluble Aβ oligomers have been
reported in AD to be organized into different structures ranging
from dimers (Walsh et al., 2000), trimers (Walsh et al., 2000; Chen
and Glabe, 2006), tetramers (Walsh et al., 2000; Chen and Glabe,
2006), pentamers and decamers (Ahmed et al., 2010), Aβ-derived
diffusible ligands (ADDLs) (Hepler et al., 2006; Lambert et al.,
1998), dodecamers, and Aβ*56 (Lesne et al., 2006).
Toxic soluble oligomers are distinct from the monomers or higher
aggregates, such as ﬁbrils, and were identiﬁed in AD brains (Kayed
et al., 2003). Based on the published data, we suggest that there is an in-
verse correlation between the size of Aβ assemblies and the potency of
their exerted toxicity. As the size of the oligomeric assembly increases,
its deleterious effects decrease (Fig. 1). Aβ dimers have been shown to
assemble forming a more stable structure of higher molecular weight,
termed protoﬁbrils which are neurotoxic. Thus, dimeric units of Aβ
have been considered to be an important entity providing the building
blocks for the toxic aggregates (O'Nuallain et al., 2010; Mc Donald
et al., 2015; Garzon-Rodriguez et al., 2000). On the contrary, in vivo
micro-dialysis of mice that display age dependent plaque pathology
did not detect the presence of the dimers at any age (Hong et al.,
2011). It was also noticed that oligomers can form from secondary
nucleation (Cohen et al., 2013). Recent studies have shown that there
are at least 2 types of oligomers with type 1 being relatively more
Fig. 1. The relationship between the size of Aβ assemblies and their toxic effects. Over produced native Aβ peptides undergo misfolding and form aggregates of different sizes and shapes.
As the size of the assemblies increases, the potency of their toxic effects decreases maintaining an inverse correlation. For Aβ, toxic oligomers likely range from 8-24 mers while α-syn
oligomers are 6-18 mers and tau oligomers are 3-15 mers. These n-mers cause neuronal toxicity either directly or by building up the higher aggregates. As these aggregates mature
more into ﬁbrils (bottom part of the funnel), they become less potent in their toxicity.
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species of Aβ oligomers. Dodecamers and Aβ*56 appear to be diffuse
throughout the tissue and exert toxic effects in cultures. Aβ*56
oligomers contain mainly replicates of Aβ trimers and were identiﬁed
in the brains Tg2576 mice (Lesne et al., 2006). This soluble aggregate
of Aβ appeared to impair memory function in these animals, irrespec-
tive of neuronal loss and led to synaptic dysfunction in humans (Lesne
et al., 2013; Lesne et al., 2006; Lesné et al., 2008). Consistent with its
toxic effects, these Aβ*56 oligomers were also found to correlate with
markers of synapse dysfunction and levels of hyperphosphorylated
tau (Zahs and Ashe, 2013). This suggests that toxicity is dependent on
the size, aggregation state, and diffusion of Aβ oligomers. However,
while Aβ*56 has been shown to be toxic it has not been compared to
other oligomers for relative toxicity. It is important to identify these
toxic oligomers and determine which are the most pathologically
relevant to disease in order to target the most potent oligomers in
treatment.
The role of different cleavage variants, Aβ1–40 and Aβ1–42, has
been under investigation for some time. They are the 2 dominant Aβ
peptides produced by β-secretase and γ-secretase. In vitro, Aβ1–40
tends to be more stable in isolation and remains in the monomer
stage longer before it aggregates to form ﬁbrils. The authors also
found that Aβ1–42 tends to remain in a mix of monomer, trimer, and
tetramer until it aggregates into ﬁbrils (Chang and Chen, 2014). It is
notable that when the study mixed Aβ1–40 and Aβ1–42 in equimolar
ratio the oligomers that formed were spherical and were the most
toxic oligomers when applied to culture (Chang and Chen, 2014).
Another group conﬁrmed and extended these ﬁndings by applying
Aβ1–40, Aβ1–42, and mixed Aβ oligomers onto cultured neurons and
observed that themixed Aβ1–40 and Aβ1–42 formed smaller oligomers
on neurites than either pure peptide alone and that larger aggregates
were observed in vitro on glass slides suggesting that the aggregation
pathway is different in cell free applications versus culture (Johnson
et al., 2013). These ﬁndings and others like them suggest an important
role for the ratio of Aβ1–42 to Aβ1–40 in toxicity and that they
interact to produce smaller, more stable, and more toxic structures.Since Aβ1–42 to Aβ1–40 ratio is known to be elevated in familial AD
it could prove to be relevant in therapeutic interventions. Our laborato-
ry recently developed and characterized a new antibody known as VIA
which recognizes only Aβ1–42 oligomers. This antibody does not bind
monomeric or ﬁbrillar Aβ1–42 or any form of Aβ1–40. VIA has applica-
tions in helping us elucidate the role of Aβ1–42 oligomers in disease
pathogenesis and may have potential as an immunotherapy (Bodani
et al., 2015). Studies like these also suggest that Aβ oligomers form
different strains, or structures depending on the speciﬁc length of the
Aβ peptide and how it folds.
Membrane disruption and ion dysregulation are known components
of Aβ toxicity. Aβ oligomers have also been shown to directly interact
with membranes forming pores and disrupting the proper permeability
ofmembranes (Kayed and Lasagna-Reeves, 2013). A distinct pore struc-
tured oligomer termed an annular protoﬁbril may be responsible to this
ion dysregulation. Our group showed that these annular protoﬁbrils are
associated with activated astrocytes and escape ﬁbrillization in vitro
and in vivo (Lasagna-Reeves et al., 2011; Lasagna-Reeves and Kayed,
2011). Another study used simulations to investigate oligomer insertion
into a lipid bilayer and suggests that a U-shaped trimer is the smallest
oligomer capable of inserting into the membrane while maintaining
its structure and then assembling into pores (Jang et al., 2013). The
study also suggests that monomers and dimers may insert into the
membrane but require interaction with other Aβ oligomers to form
the toxic pores (Jang et al., 2013). Other studies showed that Aβ
oligomers exert their toxic effects through certain receptors. Data
obtained from combined studies of electrophysiology, biochemistry,
and immunohistochemistry showed that soluble Aβ oligomers, even
at very low molecular concentration, inhibit LTP by increasing NMDA
response through NR-2B containing NMDA-receptors (Li et al., 2011).
These oligomers were also shown to bind to the PrPc and lead to a series
of events disrupting synaptic function in hippocampal neurons (Freir
et al., 2011; Lauren et al., 2009; Um et al., 2012). Another group recently
showed that small Aβ1–42 oligomers cause rapid depolarization of
neurons leading to the release of glutamate and excitotoxicity due to
Ca2+ entry. Microglia were also shown to be depolarized by Aβ1–42
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The study also showed that Aβ oligomers may sensitize the mitochon-
drial permeability transition pore to Ca2+ resulting in mitochondrial
dysfunction and cell death (Morkuniene et al., 2015). The mitochondria
are implicated in Aβ induced toxicity through many mechanisms rang-
ing from Ca2+ dysregulation to Aβ induced signaling and metabolism
disruption (reviewed by Kaminsky et al. (2015)). These studies suggest
that Aβ can interactwith themembrane in potentially differentways in-
dicating that targeting one conformationmay not be enough to stop AD.
Additionally, blocking Aβ oligomerization protected cells from toxicity
while compounds that simply block ﬁbril formation did not protect
cells in culture (De Felice et al., 2004). Thioﬂavin-T (ThT) is a compound
which ﬂuoresces when it binds to Aβ ﬁbrils and can be used to monitor
ﬁbril formation.When ThT positive ﬁbrilswere used to seedmonomeric
Aβ, the monomers formed ﬁbrils quickly rather than higher order olig-
omers.When these ThT positiveﬁbrilswere added to a culturewithmo-
nomeric Aβ, theywere less toxic thanwhenmonomeric Aβwas applied
alone. The authors suggested that this was due to decreased formation
of oligomers (Wu et al., 2013). However, ThT-positive inert ﬁbrils
form smaller toxic aggregates by sonication (discussed later). These
oligomeric aggregates are bis-ANS-positive, another widely used ﬂuo-
rescent dye for hydrophobicity (Guerrero-Munoz et al., 2013). There-
fore, ThT-positive ﬁbrils are less toxic compared to bis-ANS-positive
oligomers (illustrated in Fig. 2). Finally, the existence of individuals
who are non-demented with AD neuropathology indicates that ﬁbrils
and plaques are not toxic forms of Aβ. It has been suggested that these
individuals may be resistant to cognitive decline due to a lack of Aβ
oligomers binding to the synapse (Bjorklund et al., 2012). Furthermore,
these studies provide further support for the strain hypothesis
mentioned previously by indicating that there are different structures
formed by Aβ oligomers which have differing toxicities.
Studies using conformational antibodies are indicating that these
strains play important roles in toxicity. Sebollela et al. (2014) have
shown that NU4, a conformational monoclonal antibody, protected
cultured cells from Aβ induced reactive oxygen species production.
The study also found that NU4 recognized a single oligomer strain at
80 kD suggesting that it was one of the toxic species of Aβ (Sebollela
et al., 2014). However, the toxicity of the 80kD oligomer has not beenFig. 2. The relationship between the Aβ assemblies and their toxicity based upon binding with
formation and decreased toxicity (in percentage). ThT and bis-ANS binding to proteins are mo
Even though ThT reacts with the preﬁbrillar oligomers, its strongest association occurs only
more homogeneous ﬁbril species (~100% ﬁbrils) show less toxicity. On the other hand, bis-A
As the oligomers develop into larger and more stable aggregates, bis-ANS binding diminishes acompared to other oligomers to determine its relative toxicity. It is
important to conduct these studies to determine the interrelationship
between the size and the conformation in toxicity.3. Propagation of Aβ Oligomers
Insoluble ﬁbrils seeded larger Congo red-positive deposits which
were distributed unevenly throughout the injection site, whereas,
smaller soluble assemblies develop more uniformly distributed Congo
red-negative deposits (reviewed by Langer et al. (2011)). These studies
are in accordance with the observation that sonicated prion ﬁbrils
caused more potent seeding than unsonicated ones (Silveira et al.,
2005). The observation that ﬁbril-induced deposits are minimal com-
pared to the more spread out development of Aβ aggregates seeded
by soluble oligomeric assemblies is summarized in Fig. 3. The role of am-
yloid spreading in disease pathogenesiswasﬁrst discovered for the neu-
rodegenerative disease caused by the misfolding of PrPc which
generated an infectious prion protein called scrapie (PrPsc). Recently,
it has been shown that there are numerous species of Aβ oligomers
with different propagation rates and distinct toxicity in ADpathogenesis
(Musiek and Holtzman, 2015). It is suggested that the spreading of AD
pathology in different regions of the brain follows a prion-like seeding
mechanism for proteinaceous aggregates of Aβ and tau mediated by
neurons (Walker and Jucker, 2015). Like aggregated Aβ variants, het-
erogeneous tau aggregates exist in different tauopathies. It was also
shown that tau assemblies seed fromneuron to neuron and thus the pa-
thology was spread to multiple brain regions (Clavaguera et al., 2015).
Tau oligomers, not the neuroﬁbrillary tangles, seed and propagate in
various tauopathies (Gerson and Kayed, 2013). Additionally, tau trimers
were shown to be the minimal seeding unit for propagation which is
also neurotoxic (Mirbaha et al., 2015). Similarly, aggregates of α-syn,
the prime pathognomonic protein assemblies in synucleinopathies,
seed and propagate in a prion-like manner. It holds the same for other
neurodegenerative disorders (Walker and Jucker, 2015). We have
previously shown that Aβ oligomers act as seeds for other proteins,
α-syn, PrPc, and TDP-43 to form pathogenic oligomeric aggregates
(Guerrero-Munoz et al., 2014b).ﬂuorescent probes. As bis-ANS binding decreases, ThT binding increases indicating ﬁbril
stly used to conﬁrm their ﬁbrillar or oligomeric nature, respectively (more hydrophobic).
in the presence of mature ﬁbrils. Amyloid oligomers show maximum toxicity, whereas,
NS interacts most strongly (~100%) with the oligomers which show the highest toxicity.
nd so does the toxicity.
Fig. 3. Smaller aggregates are effective and potent seeds for the spreading of Aβ. Intact mature ﬁbrils might induce larger aggregates which are localized to the induction site. Sonicated
ﬁbrils form smaller assemblies with larger numbers of nucleation sites that seed more potently in local regions and can travel between anatomically connected regions, thus inducing
aggregates in distal regions.
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Inﬂammation has been a known component of AD for years, howev-
er, until the last 10 years it was largely ignored as a byproduct of the
disease that did not contribute to its progression. Inﬂammation has
been shown to be anything but trivial and Aβ oligomers have been im-
plicated in initiating the inﬂammatory process (Minter et al., 2015).
Aβ1–42 oligomers have been suggested to promote the maturation of
inﬁltrating peripheral monocytes into phagocytic microglia while
monomeric Aβ1–42 or ﬁbrillar Aβ1–42 did not (Crouse et al., 2009).
Aβ oligomers have been associated with many membrane proteins in
the synapse (Dinamarca et al., 2012) and in astrocytes and microglia
(Walker et al., 2015). Many of the synaptic receptors increase the
Ca2+ concentration in the post-synapse leading to inﬂammation and
cell death. These receptors include NMDA and mGluR receptors
(Dinamarca et al., 2012). In addition to aberrant Ca2+ concentrations,
Aβ oligomers have been linked to the receptor for advanced glycation
end products (RAGEs) which is a microglial receptor leading to the
activation of pro-inﬂammatory pathways and was found to be elevated
in AD (Walker et al., 2015). RAGE is also implicated in hypertension,
cardiovascular diseases, diabetes, stroke, and traumatic brain injury
which are all known risk factors for the development of AD. These risk
factors are all linked to RAGE and Aβ production through its many
ligands (reviewed by Matrone et al. (2015)). Furthermore, phase II
clinical trials with a RAGE inhibitor called TTP448 are having beneﬁcial
effects with low toxicity in AD patients (Walker et al., 2015). Together,
these studies suggest that inhibiting RAGE may have therapeutic
potential in order to decrease or prevent Aβ induced inﬂammatory
damage to the brain.
It is interesting to note that most of the current research indicates
that Aβ oligomers are inducing inﬂammation through several receptors
such asRAGE, Toll-like receptors, nod-like receptors, and formyl peptide
receptors (Minter et al., 2015; He et al., 2012) but there are still conﬂict-
ing reports on which strain of Aβ is inducing the inﬂammation (Ferrera
et al., 2014). Inﬂammation appears prior to the formation of larger
aggregates suggesting that the smaller oligomers, which form ﬁrst, are
initiating this inﬂammation. Conﬂicting reports about Aβ ﬁbrils or
oligomers inducing inﬂammation could easily be the result of different
methods. Studies on in vitro microglia cultures implicate Aβ ﬁbrils
(Ferrera et al., 2014) while, in vivo mouse injections implicate Aβ
oligomers in causing inﬂammation (He et al., 2012). Or it could be the
difference in acute responses versus prolonged responses in the
aforementioned studies.
Inﬂammation is one of the earliest signs of AD beginning prior to the
formation of Aβ plaques as mentioned above. While there is evidence
that Aβ is inducing the inﬂammation through many mechanisms such
as receptor mediated or direct interaction with the membrane, it isstill debated which came ﬁrst: oligomer or inﬂammation. Understand-
ing the sequence of events at this stage could provide insight into the
mechanisms bywhich pathology spreads. For example, does chronic in-
ﬂammation lead to the initial formation of Aβ oligomer seeds and the
spread of pathology? Or perhaps as the Aβ oligomers spread and seed
aggregation in new regions, they induce inﬂammation and accelerate
degeneration. These questions are not only relevant for Aβ oligomers
but other amyloids as well, especially tau. Tau oligomers are known to
spread locally and via synaptic connections (Boluda et al., 2015;
Ahmed et al., 2014; Asai et al., 2015). Since most amyloids are known
to spread and propagate over the course of disease, the question of
inﬂammation preceding amyloid oligomers or oligomers preceding
inﬂammation is a relevant topic for all amyloidogenic proteins.
5. Immunotherapy
Aβ immunotherapy has been a hot topic in recent yearswith the fail-
ure of several passive immunotherapies against Aβ. Many of these anti-
bodies do not discriminate between the different Aβ sizes and
conformations. Some prefer monomers but still react to larger aggre-
gates while others have targeted the plaques but also react to smaller
species. First, Solanezumab is an immunotherapy which, to date,
uniquely targets monomers and oligomers but not ﬁbrils. However,
Solanezumab binds the monomer with higher afﬁnity which means
that the dose required to bind oligomers is much higher (Goure et al.,
2014). Preferential binding of the monomer may explain why clinical
trials failed to show improvement due to the fact that they used a
lower dosage which may have been saturated by monomers (Goure
et al., 2014; Doody et al., 2014). A similar reason was cited for the lack
of efﬁcacy of Bapineuzumab which binds monomer and oligomers
with similar afﬁnity but since oligomers are much less prevalent the
dosage used may not have been adequate to see improvements
(Goure et al., 2014). Bapineuzumab andmost of the other immunother-
apies tested recognize ﬁbril Aβ as well as the smaller species.
Additionally, antibodies that selectively recognize Aβ1–40 or Aβ1–42,
Ponezumab and BiiB037 respectively, but do not discriminate between
sizes did not prove to be effective (Goure et al., 2014). Ponezumab de-
creased plaque burden in 20 month old Tg2576 mice indicating that it
may act by disaggregating plaques which may not be beneﬁcial
(discussed later) (Carty et al., 2006). BiiB037 binds ﬁbrils and oligomers
with high afﬁnity (Goure et al., 2014). These studies may indicate that
speciﬁc targeting of one peptide, Aβ1–40 or Aβ1–42, may not be an ef-
fective target for immunotherapy or they may suffer from the same
problem as other immunotherapies which are their lack of speciﬁcity
for oligomeric Aβ1–40 or Aβ1–42. For a complete review on the targets
of the major clinical trials see Goure et al. (2014). These trials and stud-
ies have shown that unspeciﬁc targeting or the targeting of plaques is
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indicate that targeting oligomers requires an antibody with lower afﬁn-
ity for the monomer, while Ponezumab and BiiB037 indicate that the
size of the aggregate may be more important than the peptide isoform.
This lack of speciﬁcity for the oligomer has stimulated research into
more selective antibodies. With the lack of effective or safe immuno-
therapies, there has been a push to improve speciﬁcity with the idea
that side effects can be minimized. Many researchers have managed to
create monomer or ﬁbril speciﬁc antibodies. Antibodies which target
theN-terminal of Aβ can bind to ﬁbrils and have been shown to increase
the concentration of oligomers and thus increased toxicity through
disaggregation (Liu et al., 2015b). Liu et al. (2015b) did not ﬁnd the
same increase in oligomer concentration when using C-terminal or
mid-peptide recognizing antibodies. Another group tested a monomer
speciﬁc antibody which was a precursor to Solanezumab. In J20 mice
the Aβ concentration bound to the antibody in the blood increased
but the oligomeric concentration in the cortex did not change nor did
cognition improve (Mably et al., 2015). The study also tested a ﬁbril
antibody 1C22 which increased free Aβ in the blood but also did not
inﬂuence cerebral oligomer levels or cognition (Mably et al., 2015).
Additionally, 20% of the J20 mice immunized with either antibody
died during the course of the study while control and PDAPP mice did
not show the samemortality. These results indicate that extensive safe-
ty studies need to be pursued but Mably et al. (2015) did not look into
the cause of death for these mice. These studies suggest that a speciﬁc
oligomer antibody may be required to effectively improve cognition
and decrease side effects. In 2014, a studywas published which indicat-
ed the use of an oligomer speciﬁc conformation antibody eliminated
synapse loss distant from plaques in Tg2576 mice and attenuated syn-
apse loss in proximity to the plaques (Dorostkar et al., 2014). This
group did not conduct behavior tests but it suggests that cognition
could be improved with these antibodies. Additionally, Dorostkar et al.
(2014) did not ﬁnd signiﬁcant changes with the IgG or pan-Aβ antibod-
ies used. Oligomer speciﬁc antibodies need to be investigated more
thoroughly to prove their efﬁcacy and safety.
While most studies support the idea for the use of Aβ oligomer spe-
ciﬁc antibodies as therapeutics, there are some researchers arguing that
these antibodies are still toxic and may increase the toxicity of Aβ olig-
omers. One study aiming to explain the meningoencephalitis seen in
clinical trials looked at several antibodies which bind different forms
of Aβ: Aβ1–40 and Aβ1–42 (Morkuniene et al., 2013). In the presence
of microglia the antibody #11E12, in complex with either Aβ1–40 or
Aβ1–42 oligomers, was more toxic than when oligomers were applied
alone. The authors suggest that the microglia FcγR receptor was
mediating this interaction (Morkuniene et al., 2013). However, it is
important to note that the antibody used in this study recognized the
N-terminal which has been shown to increase toxicity by disaggregat-
ing ﬁbrillar Aβ into oligomers and they did not investigate other
antibodies that recognize the C-terminal or middle sections of Aβ. The
use of N-terminal antibodies could be disastrous if these mechanisms
act synergistically by increasing oligomer and antibody–antigen
complex concentration and increasing oligomer concentration through
the disaggregation of ﬁbrillar Aβ. However, there is another potential
reason for the increased toxicity of these antibodies when complexed
with oligomers. The peripheral sink hypothesis states that the
antibody–antigen complex may be cleared from the brain through the
blood creating a decrease, or sink, in the Aβ levels in the brain. This
mechanism of clearance cannot be tested in culture since the
Aβ-antibody complex remains in the media. To test these concepts, it
would be interesting to see if these results can be validated in vivo
through the use ofmicroglia suppressors aswell as investigating the pe-
ripheral sink hypothesis through serum analysis. Further research into
immunotherapies is warranted with an emphasis on oligomer speciﬁc
antibodies but many obstacles remain. Immunotherapy studies need
to start including inﬂammationmarkers to better predict complications
in humans. Antibodies targeting a region of the peptide sequence arenot proving to be effective and cross react with too many forms of Aβ.
Perhaps conformational antibodies are the key to targeting the
oligomers speciﬁcally. It was suggested several years ago that the
sequence may not be as important as the conformation in producing
toxicity. A generic amyloid oligomer antibody proved effective at reduc-
ing plaque burden with decreased microhemorrhaging (Rasool et al.,
2012). It is important to point out that this antibody selectively recog-
nized oligomers but did not differentiate between amyloid proteins
such as Aβ and tau. Rasool et al. (2012) also conducted active immuni-
zation prior to the appearance of plaques in the Tg2576 mouse model
and the random sequence oligomer antigen produced less autoimmune
response than active immunization with Aβ. The random sequence
oligomer antigen was made from a random 20mer sequence of 8
amino acids, had low homology to human proteins, and strongly
reacted with A11 oligomer speciﬁc antibody (Rasool et al., 2012). This
study was followed by a report that monoclonal amyloid oligomer
antibodies, made from this random sequence oligomer antigen, admin-
istered by passive immunization reduced plaque burden, reduced
hyperphosphorylated tau, and improved cognition in 3xTg-AD mice
(Rasool et al., 2013). To our knowledge, these studies have not been
extended further in the last few years but warrant further investigation
due to their efﬁcacy and decreased inﬂammatory responses. Passive
immunotherapy targeting oligomeric conformations is still the most
promising avenue towards treating AD. Targeting toxic oligomers
from different proteinswith a single antibody which recognizes confor-
mational similarities would likely be therapeutically beneﬁcial since
many disease including AD are characterized by aggregates of multiple
proteins (Guerrero-Munoz et al., 2014a; Rasool et al., 2013; Kayed and
Glabe, 2006; Kayed et al., 2003; Kayed and Lasagna-Reeves, 2013). Olig-
omer speciﬁc immunotherapy is proving to be effective in rodent and
culture studies but needs to be extended into clinical trials.
Removing plaques from the brains of AD patients does not appear to
be effective and the targeting of oligomeric forms of Aβ seems to be the
most promising therapeutic in development. The mechanism by which
these antibodies work is thought to be through the binding of extracel-
lular oligomers preventing the spread of the pathology and they do not
bind to plaques. These antibodies do not need to be able to get inside
cells but can instead reduce or eliminate the cell to cell spread of Aβ
oligomers preventing oligomers from seeding pathology in new regions
or initiating inﬂammation. Other amyloids such as α-syn and tau are
also showing reduced spreading and degeneration using immunothera-
py suggesting that Aβ oligomers could be similar. Several studies
support this idea that the antibodies work by binding extracellular
amyloids and prevent the spread of the seeds into new regions
(Valera and Masliah, 2015; Sankaranarayanan et al., 2015; Valera
et al., 2015). Thus, these antibodies prevent the progression of the
pathology. Another study showed that an antibody to α-syn protected
cells in culture by binding to it and preventing it from entering the
cell and seeding the endogenous α-syn (Tran et al., 2014). Preventing
the spread of pathology could be key in treating AD. Additionally,
combination therapies targeting Aβ oligomers alongwith inﬂammation
or other amyloid oligomers could provide the edge that many of these
therapies lack on their own. Such treatments have already been called
for by the α-syn ﬁeld and may apply to other amyloids such as Aβ
(Valera and Masliah, 2015). Removing Aβ oligomers while inhibiting
inﬂammation and reducing other amyloid oligomers could work syner-
gistically by targeting key problem areas in this multifactorial disease.
6. Outstanding Questions
While we know more about AD and Aβ oligomers than ever before,
there are still some outstanding questions that need to be answered. For
example, how important are conformation, size, and their interplay in
determining the toxicity of Aβ oligomers. The development of confor-
mation speciﬁc, sequence independent antibodies is facilitating this
search. Additionally, which comes ﬁrst, inﬂammation or oligomers?
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for positive feedback in the inﬂammatory pathway but could have a
profound impact on how we view AD. Furthermore, is inhibiting the
spread of Aβ oligomers, or a subset of Aβ oligomers, sufﬁcient to delay
or stop the progression of AD or dowe need to investigatemultifactorial
treatments. Immunotherapy targeting Aβ oligomers speciﬁcally is
effective in rodents but human trials need to be conducted to determine
their safety and efﬁcacy. However, multifactorial treatments appear to
be the most promising as it has recently been shown that multiple pro-
tein species spread in neurodegenerative diseases. Furthermore, immu-
notherapy against multiple amyloid oligomers or in combination with
anti-inﬂammatory treatments has the potential to work synergistically.
It is essential that we answer these questions in order to advance our
understanding of AD and therapeutic development. Oligomer speciﬁc
antibodies may be the treatment for AD we have been searching for or
we may need to reﬁne our theories further, but we cannot move
forward without answering these questions. There is a current push
for anti-oligomer treatments with promising results seen in animal
studies but we are at the critical test for this hypothesis: will they
work alone or in combination with other therapies in humans?
7. Search Strategy and Selection Criteria
Articles used for this review were identiﬁed from PubMed searches
using keywords such as “amyloid-β”, “oligomers”, “conformations”,
“inﬂammation”, “immunotherapy”, “spreading”, and “Alzheimer's
disease”. Peer reviewed sources written in English were used, and
news and reports were excluded.
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